The Prevention, Early Detection, & Effective Management Of Neurocognitive Disorders In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$4,929,014.00
Summary
The unprecedented greying of the world population is posing a major challenge to health care in meeting the needs of older individuals with cognitive disorders such as Alzheimer�s disease. At the same time, drugs are being developed to prevent these disorders, or to treat them effectively. Our proposal is a comprehensive attempt at dealing with the neuropsychiatric aspects of these neurocognitive disorders. Our group is endeavouring to better define the early stages of these disorders, and study ....The unprecedented greying of the world population is posing a major challenge to health care in meeting the needs of older individuals with cognitive disorders such as Alzheimer�s disease. At the same time, drugs are being developed to prevent these disorders, or to treat them effectively. Our proposal is a comprehensive attempt at dealing with the neuropsychiatric aspects of these neurocognitive disorders. Our group is endeavouring to better define the early stages of these disorders, and studying methods of detecting them at an early stage, using the latest neuropsychological and neuroimaging techniques. We wish to investigate new drugs for the prevention of dementia. Much of dementia is not treated early because of lack of training of primary care physicians in identifying dementia, and we are developing methods to deal with this problem. We are also examining the role of cognitive disorders in accidents and suicides in the elderly, and the development of depression. We are determining the role of psychiatric disorders in the care of these patients, and the methods of alleviating the burden of disease. We expect that this research will make a major impact on health policy for these disorders in Australia. We also hope to make our Program the premier centre for training in geriatric neuropsychiatry.Read moreRead less
Prevention, Early Detection And Effective Management Of Neurocognitive Disorders In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$6,547,975.00
Summary
The Program comprises a number of longitudinal studies of ageing individuals to develop methods of diagnosing dementia before symptoms become prominent. We are also examining factors that increase the risk of developing dementia. We wish to translate this research into early and better diagnosis, and the development of new treatments and strategies for dementia care. We expect that this research will make a major impact on health policy in Australia for cognitive disorders in the elderly.
Neourobiology Of Human Epilepsy: Genes, Cellular Mechanisms,network And Whole Brain
Funder
National Health and Medical Research Council
Funding Amount
$17,652,824.00
Summary
The team is comprised of neurologists, molecular geneticists, physiologists and brain imaging specialists and leads the world in the discovery of the genetic causes of epilepsy. They will continue to identify genes underlying epilepsy and study how genetic variations result in development of seizures. Advanced brain imaging will be used to understand the effects of genetic variation on brain structure and function. This study may lead to new diagnostic methods and treatments for epilepsy.
Posttraumatic Mental Health: Advancing Understanding Of Diagnosis, Treatment And Mechanisms
Funder
National Health and Medical Research Council
Funding Amount
$7,590,920.00
Summary
Psychological disorders following exposure to trauma account for a significant proportion of the burden of disease in terms of personal suffering, decreased productivity, occupational dysfunction, and demands on health services. This project will enhance the nation's capacity to reduce psychological problems after trauma. This project will consolidate a critical mass of Australia's leading trauma researchers that will ensure that Australia retains its leading edge in posttraumatic research.
Many new therapies are being developed to treat stroke and prevent its recurrence. While a number of these have been successfully introduced, there is a puzzling gap between evidence of efficacy in animal models and humans. One of the main reasons may be lack of an integrated approach between the basic sciences and clinical researchers. By assembling a team with skills in both areas and a structure to maximise communication between groups this team plan to incrementally introduce new therapies i ....Many new therapies are being developed to treat stroke and prevent its recurrence. While a number of these have been successfully introduced, there is a puzzling gap between evidence of efficacy in animal models and humans. One of the main reasons may be lack of an integrated approach between the basic sciences and clinical researchers. By assembling a team with skills in both areas and a structure to maximise communication between groups this team plan to incrementally introduce new therapies into clinical practice.Read moreRead less
IMPROVING STROKE OUTCOMES: NEW TARGETS AND THERAPIES
Funder
National Health and Medical Research Council
Funding Amount
$7,212,064.00
Summary
Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using ....Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using the clot dissolving agent tPA to extend the time during which the drug may be effective beyond the three-hours currently used. In the next phase of our program we plan to expand the basic science component to identify parts of brain cells (axons and dendrites) which may yield important information about new drugs to protect the brain. We will use our novel summary data technique to test drugs in animal models more appropriate to the human stroke paradigm than have been used in the past In clinical studies we will follow our theme of identifying new targets for therapy using sophisticated PET and MRI imaging techniques, both in patients who are at great risk of stroke recurrence after a minor warning stroke and those with stroke caused by bleeding within the brain. These studies will provide information about predictors of recurrent and worsening stroke which may be modified by new therapies. The final stage in identifying new therapies is the Phase III clinical trial. We will complete one of these in which the most appropriate drug preventing further strokes in a major new stroke subtype will be identified. Toward the end of the program, we will commence phase 3 studies of drugs we have selected as being most likely to protect the brain based on our animal experiments. The main benefit of this unique collaborative research model is to efficiently identify new therapies to reduce the burden of stroke, currently the second most common cause of death globally.Read moreRead less